Literature DB >> 9788354

Formation of a catalytically active dimer by tRNA(Val)-driven short ribozymes.

T Kuwabara1, M Warashina, M Orita, S Koseki, J Ohkawa, K Taira.   

Abstract

A minizyme is a hammerhead ribozyme with a short oligonucleotide linker instead of stem/loop II. Minizymes with low activity as monomers form active dimeric structures with a common stem. We explored the use of dimeric minizymes as gene-inactivating agents by placing minizymes under the control of a tRNA(Val) promoter. The tRNA(Val) portion of the transcript did not hinder dimerization as the tRNA-embedded minizyme formed an active dimeric structure. The cleavage activity of this minizyme that had been expressed either in vitro or in HeLa cells was almost one order of magnitude higher than that of the tRNA(Val)-embedded conventional hammerhead ribozyme. The tRNA(Val)-driven minizyme inhibited reporter gene activity (95%) whereas the tRNA(Val)-driven hammerhead ribozyme resulted in approximately 55% inhibition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788354     DOI: 10.1038/nbt1098-961

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  14 in total

1.  Reduction of target gene expression by a modified U1 snRNA.

Authors:  S A Beckley; P Liu; M L Stover; S I Gunderson; A C Lichtler; D W Rowe
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

Review 2.  Recent advances in the elucidation of the mechanisms of action of ribozymes.

Authors:  Y Takagi; M Warashina; W J Stec; K Yoshinari; K Taira
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

3.  Cooperative binding of effectors by an allosteric ribozyme.

Authors:  A M Jose; G A Soukup; R R Breaker
Journal:  Nucleic Acids Res       Date:  2001-04-01       Impact factor: 16.971

4.  Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells.

Authors:  T Kuwabara; M Warashina; S Koseki; M Sano; J Ohkawa; K Nakayama; K Taira
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

5.  RNA-protein hybrid ribozymes that efficiently cleave any mRNA independently of the structure of the target RNA.

Authors:  M Warashina; T Kuwabara; Y Kato; M Sano; K Taira
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

6.  Maxizyme-mediated specific inhibition on mutant-type p53 in vitro.

Authors:  Xin-Juan Kong; Yu-Hu Song; Ju-Sheng Lin; Huan-Jun Huang; Nan-Xia Wang; Nan-Zhi Liu; Bin Li; You-Xin Jin
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

7.  RNA nanotechnology for computer design and in vivo computation.

Authors:  Meikang Qiu; Emil Khisamutdinov; Zhengyi Zhao; Cheryl Pan; Jeong-Woo Choi; Neocles B Leontis; Peixuan Guo
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2013-09-02       Impact factor: 4.226

8.  Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III.

Authors:  S Koseki; T Tanabe; K Tani; S Asano; T Shioda; Y Nagai; T Shimada; J Ohkawa; K Taira
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  tRNAVal-heterodimeric maxizymes with high potential as geneinactivating agents: simultaneous cleavage at two sites in HIV-1 Tat mRNA in cultured cells.

Authors:  T Kuwabara; M Warashina; A Nakayama; J Ohkawa; K Taira
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 10.  The emerging field of RNA nanotechnology.

Authors:  Peixuan Guo
Journal:  Nat Nanotechnol       Date:  2010-11-21       Impact factor: 39.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.